No Sustained Benefit, Risk To Cognitive Function Of Postmenopausal Hormone Therapy Prescribed To Women Ages 50 To 55 Years

Postmenopausal hormone therapy with conjugated equine estrogens (CEEs) was not associated with overall sustained benefit or risk to cognitive function when given to women ages 50 to 55 years, according to a report published Online First by JAMA Internal Medicine, a JAMA Network publication. The Women's Health Initiative Memory Study (WHIMS) demonstrated that postmenopausal hormone therapy with CEEs, when prescribed to women 65 years and older, caused deficits in global and domainspecific cognitive functioning...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Endocrinology Source Type: news